Wunderlich Reiterates Buy Rating On Abiomed

by BenzingaStaffB, Benzinga Staff Writer
August 4, 2011 12:46 PM | 14 seconds read |
According to Wunderlich Securities, Abiomed ABMD reported fiscal Q4 revenues this morning, essentially right in line with the estimates. Wunderlich said that revenues grew 25%, while Impella increased 33%. "We reiterate our Buy rating and $24 target." Abiomed closed yesterday at $15.24.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Analyst ColorAnalyst RatingsHealth CareHealth Care EquipmentWunderlich Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!